Blueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 1,834 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,834 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $103.88, for a total value of $190,515.92. Following the transaction, the insider now owns 14,913 shares in the company, valued at approximately $1,549,162.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Blueprint Medicines Price Performance

BPMC stock opened at $106.25 on Tuesday. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $110.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76. The stock’s 50 day moving average price is $91.77 and its 200 day moving average price is $80.95. The firm has a market cap of $6.50 billion, a P/E ratio of -22.09 and a beta of 0.65.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the prior year, the company posted ($2.65) EPS. The business’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, sell-side analysts expect that Blueprint Medicines Co. will post -5.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Stifel Nicolaus boosted their target price on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday. Citigroup upped their price target on Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a report on Friday. The Goldman Sachs Group upped their price target on Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a report on Monday. Finally, HC Wainwright upped their price target on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.31.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Blueprint Medicines by 0.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after purchasing an additional 145 shares during the period. Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 193 shares during the period. Principal Financial Group Inc. raised its position in shares of Blueprint Medicines by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 247 shares during the period. Diversified Trust Co raised its position in shares of Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after buying an additional 318 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in shares of Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after buying an additional 329 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.